Amgen, FDA and Lumakras

Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRASG12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC) whose tumors harbor an abnormal gene known as KRAS G12C.
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median progression-free survival (PFS) of 5.6 months compared to 2 months on the investigator’s choice of care (n=54).
Amgen announces FDA approval of Lumakras in combination with Vectibix
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS
Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival,
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Friday announced that the U.S. Food and Drug Administration has approved its Lumakras plus Vectibix combination
Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer
Lumakras (sotorasib) and Vectibix (panitumumab) have been authorised for use in adults with KRAS G12C-mutated metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
FDA nod for Lumakras with Vectibix combo for mCRC
The US Food and Drug Administration approved sotorasib (trade name Lumakras) with panitumumab Vectibix), from US biotech major Amgen, for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC),
FDA Approves Lumakras with Vectibix in KRAS G12C+ Colorectal Cancer
The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received chemotherapy.
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation. Amgen's Lumakras in combination with Vectibix was approved to treat adult patients whose cancer has spread to other parts of the body despite receiving chemotherapy,
FDA approves new colorectal cancer treatment
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) to treat adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
FiercePharma4h
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC C…
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...
ENDPOINTS NEWS8h
Af­ter three-month de­lay, Am­gen’s Lumakras clinch­es FDA green light in col­orec­tal can­cer
FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...